Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The blood test developer took in $165m through a series B round led by SoftBank Vision Fund 2 that came three years after a Tencent-backed series A.

Manufacturing partner WuXi Biologics participated in a series A round for the startup, which aims to transfer human biopharmaceutical practices to animal drug development.

UBC's Lab2Launch incubator will nurture embryonic inventions mainly from the life sciences sector through the validation of their concepts.

The GoHealth-backed health insurance engagement platform has now raised $53m altogether, with Health Velocity Capital leading its series C round.

Oncology therapy developer Revolution Medicines went public giving an exit to pharmaceutical company Sanofi.

The Globis-backed startup accelerator has chosen 12 participating startups for its sophomore cohort, three months after the demo day for the initial batch.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The Chalmers University of Technology back pain injection spinout floated in an IPO that was oversubscribed by more than four-fold.

Healthcare staff management platform IntelyCare attracted Kaiser Permanente Ventures as a new investor in a series B round that increased its overall funding to $59m.